慢性阻塞性肺疾病（COPD）和哮喘中基于偏好的健康测量方法（EQ-5D）的应用。

Use of a preference-based measure of health (EQ-5D) in COPD and asthma.

作者信息

Pickard A Simon, Wilke Caitlyn, Jung Eunmi, Patel Sneh, Stavem Knut, Lee Todd A

机构信息

Center for Pharmacoeconomic Research, Department of Pharmacy Practice and Pharmacy Administration, College of Pharmacy, University of Illinois at Chicago, Chicago, IL 60612, USA.

出版信息

Respir Med. 2008 Apr;102(4):519-36. doi: 10.1016/j.rmed.2007.11.016. Epub 2008 Jan 3.

DOI:10.1016/j.rmed.2007.11.016

PMID:18180151

Abstract

BACKGROUND

EQ-5D is a generic preference-based measure of health that can help to understand the impact of asthma and chronic obstructive pulmonary disease (COPD). The purpose of this paper was to synthesize literature on the validity and reliability of EQ-5D use in studies of asthma and COPD, and estimate EQ-5D utility scores associated with stage of disease.

METHODS

A structured search was conducted in EMBASE and MEDLINE (1988-2007) using keywords relevant to respiratory disease and EQ-5D. Original research studies in asthma or COPD that reported EQ-5D results and/or psychometric properties were included.

RESULTS

Studies that reported psychometric properties supported the construct validity, test-retest reliability, and responsiveness of EQ-5D in asthma (seven studies) and COPD (nine studies), although some evidence of ceiling effects were observed in asthma studies. In asthma studies that reported summary scores (n=11), EQ-5D index-based scores ranged from 0.42 (SD 0.30) to 0.93 (SD not reported). In COPD studies (n=8), scores ranged from 0.52 (SD 0.16) to 0.84 (SD 0.15). While few asthma studies reported scores by severity level, sufficient studies in COPD were available to calculate pooled mean utility scores according to GOLD stage: stage I=0.74 (0.62-0.87), stage II=0.74 (0.66-0.83), stage III=0.69 (0.60-0.78) and stage IV=0.61 (0.44-0.77) (most severe).

CONCLUSIONS

Evidence generally supported the validity and reliability of EQ-5D in asthma and COPD. Utility scores associated with COPD stage may be useful for modeling health outcomes in economic evaluations of treatments for COPD.

摘要

背景

EQ-5D是一种基于偏好的通用健康测量工具，有助于了解哮喘和慢性阻塞性肺疾病（COPD）的影响。本文的目的是综合关于EQ-5D在哮喘和COPD研究中有效性和可靠性的文献，并估计与疾病阶段相关的EQ-5D效用得分。

方法

在EMBASE和MEDLINE（1988 - 2007年）中使用与呼吸系统疾病和EQ-5D相关的关键词进行结构化检索。纳入报告了EQ-5D结果和/或心理测量特性的哮喘或COPD原始研究。

结果

报告心理测量特性的研究支持EQ-5D在哮喘（七项研究）和COPD（九项研究）中的结构效度、重测信度和反应度，尽管在哮喘研究中观察到了一些天花板效应的证据。在报告汇总得分的哮喘研究（n = 11）中，基于EQ-5D指数的得分范围为0.42（标准差0.30）至0.93（标准差未报告）。在COPD研究（n = 8）中，得分范围为0.52（标准差0.16）至0.84（标准差0.15）。虽然很少有哮喘研究按严重程度水平报告得分，但有足够的COPD研究可根据全球慢性阻塞性肺疾病倡议（GOLD）阶段计算汇总平均效用得分：I期 = 0.74（0.62 - 0.87），II期 = 0.74（0.66 - 0.83），III期 = 0.69（0.60 - 0.78），IV期 = 0.61（0.44 - 0.77）（最严重）。